Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 1998

View Archived Issues

Company Profile: Mallinckrodt

Protein Design Labs: Q4 and FY 1997 highlights

Phase I trial results of DAB389IL-2 in lymphoma

Enrollment complete in phase II trials for rPAF-AH

Glaxo Wellcome enrolls patients in phase III flu drug trials

Pfizer will copromote Searle's COX-2 inhibitors in U.S.

Independent evaluation committee requests additional OxSODrol data

BioTransplant: Q4 and FY 1997 highlights

Warner-Lambert reveals new antipsychotic benzoxazinones

Oxcarbazepine derivatives with potent anticonvulsant activity

Neurocrine Biosciences describes compounds for increasing endogenous neuropeptide levels

Selective dopamine D3 ligands described by P&U

Allergan's new antiglaucoma agents

PKC inhibitors under study at Hoechst Marion Roussel

Advisory panel recommends approval of Synercid

New octreotide formulation launched in Italy

U.S. patent will issue covering Theratechnologies' AIDS gene therapy

Xenova, Lilly collaborate on new antithrombotics

Rebif launched in Canada: first drug to delay disease progression in remitting-relapsing MS

FDA accepts The Medicines Company's NDA for Hirulog

Beneficial effects of lisinopril on progression of retinopathy in IDDM

Role of nonsteroidal antiinflammatory therapy in asthma

Lisofylline enters pivotal testing for acute lung injury

Cheung describes results of preclinical evaluation of its BPH Rx system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...